1. Ex-FDA Chief Gottlieb says regulator needs to up pace on COVID-19 drugs— Gilead won't be charging for use of experimental COVID drug, for now — FDA backs first emergency COVID-19 antibody test from Cellex — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Future of Roche Hospital Point of Care

Discussion in 'Roche' started by anonymous, Jul 9, 2018 at 8:25 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Roche POC continues to lose hospital market share as they stumble along with a glucose meter that was 5 years old when it launched in 2013. The word is they won’t have a replacement glucose meter for 3 more years.
    The Roche POC Salesforce is tasked with selling the Liat flu analyzers to hospitals where there is little interest for the device that fits better in small clinics. Competitive products are cheaper and faster giving customers no reason to select a Liat.
    Account managers haven’t made decent bonuses in a couple of years because of the heavy weighting on Liat in the bonus plan.
    All of this raises many questions:
    Will Roche exit the hospital glucose market (like J&J did a few years ago?
    Will Roche cut the size of the Salesforce?
    Will Roche exit the POC hospital space entirely?
     

  2. anonymous

    anonymous Guest

    Roche point of care is a rudderless ship.
     
  3. anonymous

    anonymous Guest

    How will inept Roche management spin the devasting news from Nova today?
     
  4. anonymous

    anonymous Guest

    Who’s selling navify? Sorry - don’t know a lot about Dia
     
  5. anonymous

    anonymous Guest

    Five years after launch, Liat is still struggling with poor strategy and marketing. The constant invalids, allocations and out of stock conditions make it difficult to sell with any integrity. Having three sales forces scrap over it has created deep seated animosity. Thank you JZ! Where is the product development? Five years and 3 assays? What a joke! Now, we are willing to give it away to get business, scrapping the service charge and lowering prices in a race to the bottom. There goes differentiation. But, go ahead and blame the salesforces for not delivering!
     
  6. anonymous

    anonymous Guest

    With no Group A Strep assay and trouble with Flu and Flu/RSV it looks like Liat is toast. Millions of dollars of business "at risk". Way to develop the product, Roche! Looks like Hospital Point of Care is headed for oblivion.
     
  7. anonymous

    anonymous Guest

    Two years after this thread was started and it looks like Roche POC is about to reorganize.